BIOHARVEST SCIENCES Business Summary

BioHarvest Sciences Inc. (BHST) operates a disruptive biotechnology business centered on its proprietary "Botanical Synthesis" platform, which enables the industrial-scale production of specific plant-based molecules in bioreactors without growing the underlying plant. The company generates revenue through two primary segments: a Direct-to-Consumer (D2C) nutraceutical division and a Contract Development and Manufacturing Organization (CDMO) unit. The D2C segment is anchored by its flagship product, VINIA—a red grape cell supplement—which utilizes a high-margin subscription model that accounts for approximately 80-90% of total revenue and supports an annualized run rate exceeding US$36 million as of early 2026. The CDMO segment provides end-to-end development and production services for pharmaceutical, cosmetic, and food companies seeking consistent, patentable plant-derived compounds. BHST competes in the specialized biotech and pharmaceutical ingredients market against firms such as Puma Biotechnology, X4 Pharmaceuticals, Amarin, and Lifecore Biomedical, distinguishing itself through its unique ability to synthesize complex secondary metabolites with superior bioavailability and environmental sustainability. The company is led by a management team with significant pedigree in global scaling and biotechnology. CEO Ilan Sobel, appointed in 2020, previously served in senior leadership roles at The Coca-Cola Company and as COO of Weissbeerger (acquired by AB InBev). The founding team includes CTO Dr. Yochi Hagay, a Ph.D. with extensive R&D leadership experience from BTG, and Chairman Dr. Zaki Rakib, a serial entrepreneur who co-founded Terayon Communication Systems. Other key executives include CFO Bar Dichter, who was elevated to the role in late 2024, and COO Dr. Ilana Belzer. The board was further strengthened by the January 2026 appointment of Sharon Malka, former CEO of Dotz Nano and CFO of MediWound, as an independent director. BioHarvest is backed by a growing base of U.S. institutional investors following a successful $19.9 million public offering in late 2025, which included participation from Magnus Financial Group and True North Advisors.